Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2019) 65 P235 | DOI: 10.1530/endoabs.65.P235

1Imperial College London, London, UK; 2University of Birmingham, Birmingham, UK


Glucagon-like peptide-1 receptor (GLP-1R) agonists are effective treatments for type 2 diabetes and obesity. We recently described ‘biased’ peptide GLP-1R agonists modelled on exendin-4 which uncouple the pronounced endocytosis that usually accompanies GLP-1R activation, leading to prolongation of intracellular signalling responses. Here, we show that the metabolic consequences of biased GLP-1R activation in vivo are dominated by improvements in blood glucose, without concomitant increases in their anorectic properties (40-fold relative preference for glycaemic vs. anorectic effects). To investigate this disparity, we have compared cell type-specific responses to biased GLP-1R agonists using in vitro beta cell and neuronal models, in case the downstream manifestations of bias differ according to the tissue in which they act. We also delivered these ligands directly into the CNS in mice to bypass the blood-brain-barrier, under which circumstances the anticipated efficacy increase of the biased agonist was restored. Biodistribution studies using the same compounds conjugated to near-infrared fluorophores, which allow deep tissue imaging of optically cleared intact brain and pancreas specimens, have also provided a means to assess whether biased ligands have equal or differential access to appetite regulatory centres in the CNS.

Volume 65

Society for Endocrinology BES 2019

Brighton, United Kingdom
11 Nov 2019 - 13 Nov 2019

Society for Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.